

February 15, 2021

To whom it may concern:

Company Name	TOHO HOLDINGS CO., LTD.
Corporate Representative	Atsushi Udoh, President and Representative Director (First Section of Tokyo Stock Exchange Securities Code:8129)
Contact:	Makoto Kawamura, Director and General Manager, Corporate Management Division and Corporate Planning and Investor Relations Department (TEL: 81-3-6838-2803)

Notice Regarding Marketing Approvals for
2 Ingredients / 5 Products of Generic Drugs for KYOSOMIRAI PHARMA

TOHO HOLDINGS CO., LTD. (Headquarters: Tokyo; President and Representative Director: Atsushi Udoh) is pleased to announce that KYOSOMIRAI PHARMA CO., LTD. (Headquarters: Tokyo; President and Representative Director: Nobuaki Hosaka), the wholly-owned subsidiary involved in pharmaceuticals manufacture and sales business, has received approvals for marketing of 2 ingredients / 5 products of generic drugs today on February 15, 2021 as below.

Products list approved for marketing

Classes	Product Name	Original Brand Name
Insomnia treatment	Eszopiclone Tablets 1mg/2mg/3mg “KMP”	Lunesta Tablets 1mg/2mg/3mg
Serotonin-norepinephrine reuptake inhibitors	Duloxetine Capsules 20mg/30mg “KMP”	CYMBALTA Capsules 20mg/30mg